| Literature DB >> 3371446 |
E Flückiger1, U Briner, B Clark, A Closse, A Enz, P Gull, A Hofmann, R Markstein, L Tolcsvai, H R Wagner.
Abstract
The profile of action in animals of CQP 201-403, a novel 8 alpha-amino-ergoline, is in most aspects that of a very potent dopaminomimetic, both as a prolactin secretion inhibitor, and at the levels of the CNS and the cardiovascular system. Qualitatively CQP 201-403 differs slightly from bromocriptine and apomorphine in its effects on the CNS (no influence on serotonin metabolism in the rat cortex; induction of masculine mounting behavior in rats) and the cardiovascular system of the dog (reflex tachycardia in response to a blood-pressure fall). In man the new compound proved to be highly active in lowering prolactin serum levels and be more potent than bromocriptine (Parlodel).Entities:
Mesh：
Substances：
Year: 1988 PMID： 3371446 DOI： 10.1007/bf01940539
Source DB: PubMed Journal: Experientia ISSN： 0014-4754